Indications for lung and heart-lung transplantation in adults;Indications de la transplantation pulmonaire et cardio-pulmonaire chez l'adulte

Revue des Maladies Respiratoires

Volumn 17, Issue 6, 2000, Pages 1119-1132

  Reynaud Gaubert, M ^a   Pison, Ch ^a   Stern, M ^a   Haloun, A ^a   Velly, J F ^a   Jacquelinet, C ^a   Navarro, J ^a   Mornex, J F ^a  

^a HÔPITAL SAINTE MARGUERITE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALGORITHM; BRONCHIECTASIS; CYSTIC FIBROSIS; FIBROSING ALVEOLITIS; HEART LUNG TRANSPLANTATION; HUMAN; LUNG EMPHYSEMA; LUNG TRANSPLANTATION; MEDICAL DECISION MAKING; PREOPERATIVE EVALUATION; PULMONARY HYPERTENSION; REVIEW; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; TREATMENT PLANNING;

ADULT; AGE FACTORS; ALGORITHMS; BRONCHIECTASIS; CYSTIC FIBROSIS; DECISION TREES; FRANCE; HEART-LUNG TRANSPLANTATION; HUMANS; HYPERTENSION, PULMONARY; LUNG DISEASES, OBSTRUCTIVE; LUNG TRANSPLANTATION; PATIENT SELECTION; PROGNOSIS; PULMONARY FIBROSIS; SURVIVAL ANALYSIS;

EID: 0034491286     PISSN: 07618425     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (119)

1. The Registry of the International Society for Heart and Lung Transplantation: Sixteen Official Report-1999
2. Critères de sélection des candidats à la transplantation pulmonaire
3. Lung transplantation
4. Lung transplantation
5. International guidelines for the selection of lung transplant candidates
6. Preoperative corticosteroids: A contraindication to lung transplantation?
7. Severe osteoporosis before and after lung transplantation
8. The epidemiology of interstitial lung diseases
9. Natural history and treated course of usual and desquamative interstitial pneumonia
10. Idiopathic pulmonary fibrosis. Clinical relevance of pathological classification
11. Nonspecific interstitial pneumonia. Individualization of a clinicopathologic entity in a series of 12 patients
12. Prognostic significance of histologic subsets in idiopathic pulmonary fibrosis
13. Survival in patients with cryptogenic fibrosing alveolitis. A population-based cohort study
14. Cortisteroids and the treatment of idiopathic pulmonary fibrosis
15. Pharmacologic therapy of idiopathic pulmonary fibrosis
16. Randomized controlled trial comparing prednisolone with cyclophosphamide and low dose prednisolone in combination in cryptogenic fibrosing alveolitis
17. Use of intermittent, intravenous cyclophosphamide for idiopathic pulmonary fibrosis
18. Azathioprine combined with prednisone in the treatment of idiopathic pulmonary fibrosis: A prospective double-blind, randomized, placebo-controlled clinical trial
19. Colchicine in the treatment of pulmonary fibrosis
20. Colchicine versus prednisone in the treatment of idiopathic pulmonary fibrosis. A randomized prospective study
21. Efficacy of cyclosporine to reduce steroids in patients with idiopathic pulmonary fibrosis before lung transplantation
22. Idiopathic pulmonary fibrosis and cyclosporine: A lesson from single-lung transplantation
23. Treatment of idiopathic pulmonary fibrosis with a new antifibrotic agent, Pirfenidone. Results of a prospective, open-label phase II study
24. A preliminary study of long-term treatment with interferon gamma-1b and low dose prednisolone in patients with idiopathic pulmonary fibrosis
25. Determinants of progression in idiopathic pulmonary fibrosis
26. Determinants of survival in idiopathic pulmonary fibrosis
27. Correlation of the structure and function in idiopathic pulmonary fibrosis
28. Idiopathic pulmonary fibrosis. Predicting response to therapy and survival
29. Predictors of survival in patients receiving domiciliary oxygen therapy or mechanical ventilation: A 10 year analysis of ANTADIR observatory
30. Treatment of diffuse parenchymal disease
31. Does lung transplantation prolong life? A comparison of survival with and without transplantation
32. Effect of diagnosis on survival benefit of lung transplantation for end-stage lung disease
33. Outcome of the native lung after single lung transplant
34. Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema
35. Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: A clinical trial
36. Pulmonary rehabilitation - 1999
37. Results of 150 consecutive bilateral lung volume reduction procedures in patients with severe emphysema
38. Lung volume reduction in patients with severe emphysema. A retrospective study
39. Lung volume reduction surgery: Official statement of the American Thoracic Society
40. Lung volume reduction surgery. Is less really more?
41. Short- and long term functional results after lung volume reduction surgery for severe emphysema
42. Prospective randomized trial comparing bilateral lung volume reduction surgery to pulmonary rehabilitation in severe chronic obstructive pulmonary disease
43. Prognosis in chronic obstructive pulmonary disease: Results from multicenter clinical trials
44. Prognostic factors in COPD patients receiving long term oxygen therapy. Importance of pulmonary arterial pressure
45. Body weight in chronic obstructive pulmonary disease: The National Institutes of Health intermittent positive-pressure breathing trial
46. Weight loss is a reversible factor in the prognosis of chronic obstructive pulmonary disease
47. Hospital and 1-year survival of patients admitted to intensive care units with acute exacerbation of chronic obstructive pulmonary disease
48. Outcomes following acute exacerbation of severe chronic obstructive lung disease
49. Airways obstruction and two years survival in patients with severe alpha 1-antitrypsin deficiency
50. Single or bilateral lung transplantation for emphysema?
51. Functional results of single-lung transplantation for chronic obstructive lung disease
52. Medium term functionnal results of single-lung transplantation for end stage obstructive lung disease
53. Comparison of outcomes after single and double lung transplantation for obstructive lung disease
54. Causes of allograft dysfunction after single lung transplantation for emphysema: Extrinsic restriction versus intrinsic obstruction
55. Volume reduction surgery in the native lung after single lung transplantation for emphysema
56. Cystic fibrosis (State of the Art)
57. Lung transplantation for cystic fibrosis. Special considerations
58. Lung transplantation in cystic fibrosis. Consensus conference statement
59. Prediction of mortality in patients with cystic fibrosis
60. Prognosis of patients with cystic fibrosis awaiting heart and lung transplantation
61. Risk of death in cystic fibrosis patients with severely compromised lung function
62. A prognostic model for the prediction of survival in cystic fibrosis
63. Infectious complications of lung transplantation. Impact of cystic fibrosis
64. Pseudomonas cepacia in lung transplant recipients with cystic fibrosis
65. Transmissibility of Pseudomonas cepacia infection in clinic patients and lung transplant recipients with cystic fibrosis
66. Post-transplantation survival of cystic fibrosis patients infected with Pseudomonas cepacia
67. Antibiotic susceptibility of multiply resistant Pseudomonas aeruginosa isolated from patients with CF including candidates for transplant
68. Allograft colonization and infections with pseudomonas in cystic fibrosis lung transplant recipients
69. The effects of panresistant bacteria in cystic fibrosis patients on lung transplant outcome
70. Lung transplantation for cystic fibrosis: Effective and durable therapy in a high-risk group
71. Lung transplantation for cystic fibrosis - A single center experience over 8 years
72. Successful lung transplantation in spite of cystic fibrosis-associated liver disease: A case series
73. Non invasive mechanical ventilation for cystic fibrosis patients - A potential bridge to transplantation
74. Epidemiology of chronic Pseudomonas aeruginosa infections in the airways of lung transplant recipients with cystic fibrosis
75. Cystic fibrosis patients who have undergone heart-lung transplantation benefit from maxillary sinus antrostomy and repeated sinus lavage
76. Role of percutaneous endoscopic gastrotomy in a malnourished patient awaiting lung transplant
77. Survival in patients with primary pulmonary hypertension
78. Pulmonary hypertension-advances in medical and surgical interventions
79. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension
80. Medical management of primary pulmonary hypertension
81. Vasodilatators in the treatment of primary pulmonary hypertension
82. Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension
83. Primary pulmonary hypertension: Improved long-term effects and survival with continuous intravenous epoprostenol infusion
84. High dose titration of calcium channel blocking agents for primary pulmonary hypertension: Guidelines for short-term drug testing
85. The effect of high-dose calcium blockers on survival in primary pulmonary hypertension
86. Effect of orally active prostacyclin analogue on survival of outpatients with primary pulmonary hypertension
87. Aerosolized prostacyclin and iloprost in severe pulmonary hypertension
88. Primary pulmonary hypertension
89. Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium-channel blockers in primary pulmonary hypertension
90. Nitric oxide and prostacyclin as test agents of vasoreactivity in severe precapillary pulmonary hypertension: Predictive ability and consequences on haemodynamics and gas exchange
91. Clinical significance of pulmonary vasodilatator response during short-term infusion of prostacyclin in primary pulmonary hypertension
92. The influence of continuous intravenous prostacyclin therapy for primary pulmonary hypertension on the timing and outcome of transplantation
93. Angioscopic video-assisted pulmonary endarteriectomy for post-embolic pulmonary hypertension
94. Blade balloon atrial septostomy in patients with severe primary pulmonary hypertension
95. Heart-lung transplantation: Successful therapy for patients with pulmonary vascular disease
96. Improved technique for bilateral lung transplantation: Rationale and initial clinical experience
97. Timing of single lung transplantation for primary pulmonary hypertension
98. Single lung transplantation for pulmonary hypertension
99. Primary pulmonary hypertension as a risk factor for the development of obliterative bronchiolitis in lung allograft recipients
100. Comparison of the hemodynamics and survival of adults with severe primary pulmonary hypertension or Eisenmenger syndrome
101. Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects
102. Lung transplantation in patients with systemic diseases: An eleven-year experience at Papworth Hospital
103. Single lung transplantation in patients with systemic disease
104. Medium term results of lung transplantation for end stage pulmonary sarcoidosis
105. Lung transplantation for lymphangio-leiomyomatosis
106. Lung transplantation for pulmonary amyloidosis: A case report
107. Prolonged survival after heart-lung transplantation in systemic lupus erythematosus
108. Lung transplantation for chemotherapy-induced pulmonary fibrosis
109. Double lung transplantation for adult respiratory distress syndrome after recombinant interleukin 2
110. Lung transplantation for respiratory failure resulting from systemic disease
111. Relapsing pulmonary Langerhans cell histiocytosis after lung transplantation
112. Recurrence of recipient Langerhans' cell histiocytosis following bilateral lung transplantation
113. Recurrence of Langerhans' cell granulomatosis following lung transplantation
114. Recurrence of sarcoidosis in pulmonary allograft recipients
115. Lymphangioleiomyomatosis: Recurrence after lung transplantation
116. Giant cell interstitial pneumonitis. Disease recurrence in the transplanted lung
117. Recurrence of bronchioloalveolar carcinoma in transplanted lungs
118. Recurrent alveolar proteinosis following double lung transplantation